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The aim of this prospective phase II trial was to determine the safety and efﬁcacy of a nonmyeloablative
conditioning program incorporating peritransplant rituximab in patients with CD20þ B cell non-Hodgkin
lymphoma (B-NHL) receiving an allogeneic stem cell transplant (allo-SCT). Fifty-one adult B-NHL patients,
with a median age of 54 years, were treated with cyclophosphamide, ﬂudarabine, and 200 cGy of total body
irradiation. Rituximab 375 mg/m2 was given on day 8 and in 4 weekly doses beginning day þ21. Equine
antithymocyte globulin was given to recipients of volunteer unrelated donor grafts. Graft-versus-host disease
(GVHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil and tacrolimus, sirolimus, and
methotrexate in 8 and 43 patients, respectively. Thirty-three patients received grafts from unrelated donors,
and 18 received grafts from matched related donors. All patients engrafted. Full donor chimerism in bone
marrow and peripheral T cells was seen in 92% and 89% of patients, respectively, at 3 months after allo-SCT.
The cumulative incidence of grades II to IV acute GVHD at 6 months was 25% (95% conﬁdence interval [CI],
13% to 38%) and grades III to IV was 11% (95% CI, 2% to 20%). The 2-year cumulative incidence of chronic GVHD
was 29% (95% CI, 15% to 44%). The 2-year event-free and overall survival for all patients was 72% (95% CI, 59%
to 85%) and 78% (95% CI, 66% to 90%), respectively. The 2-year event-free survival for chemosensitive patients
was 84% (95% CI, 72% to 96%) compared with 30% (95% CI, 2% to 58%) for chemorefractory patients before allo-
SCT (P < .001). This nonmyeloablative regimen, with peritransplant rituximab, is safe and effective in patients
with B-NHL.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite recent advances, most notably integration of anti-
CD20 monoclonal antibodies [1-4], patients with indolent
histology B cell non-Hodgkin lymphoma (B-NHL) and those
with aggressive histology B-NHL who have failed high-dose
therapy and autologous stem cell transplantation (HDT-
ASCT) are considered incurable with combination chemo-
therapy alone. Although HDT-ASCT remains the standard
of care for relapsed and refractory diffuse large B celledgments on page 359.
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13.11.029lymphoma [5], a large, multicenter prospective study pre-
sented data wherein most patients either failed to undergo
or relapsed after HDT-ASCT by intent-to-treat analysis [6].
Additionally, although HDT-ASCT has provided prolonged
remissions for patients with mantle cell lymphoma [7,8] and
follicular lymphoma (FL) [9], it is still considered to be non-
curative, and concerns of additive toxicity, including myelo-
dysplasia, remain [10].
Previously, allogeneic stem cell transplantation (allo-SCT)
with myeloablative conditioning had demonstrated favorable
NHL disease control at the expense of prohibitively high
transplant-related mortality (TRM) [11,12]. More recently,
reduced-intensity (RIC) and nonmyeloablative (NMA) condi-
tioned allo-SCT has offered favorable NHL control, attributableTransplantation.
C.S. Sauter et al. / Biol Blood Marrow Transplant 20 (2014) 354e360 355to graft-versus-lymphoma effect [13,14] and reduced TRM
[15-23]. This has permitted extension of allo-SCT to older and
more comorbid patients. The M.D. Anderson Cancer Center
previously introduced monoclonal antibody therapy with
rituximab in patients with FL undergoing an NMA allo-SCT,
predominately from matched siblings, preceded by
chemotherapy-only conditioning of ﬂudarabine and cyclo-
phosphamide with encouraging progression-free survival
[19]. Herein, we present results of a phase II study investi-
gating the integration of rituximab perieallo-SCT from
HLA-matched related and unrelated donors after NMA con-
ditioning with low-dose total body irradiation (TBI) for
patients with B-NHL.
METHODS
This was a single-center, prospective, phase II clinical trial (Memorial
Sloan-Kettering Cancer Center Internal Review Board no. 06-150). All pa-
tients provided written informed consent in accordance with federal, local,
and institutional guidelines. Rituximab was provided by Genentech, Inc
(South San Francisco, CA).
Study Objectives
The primary objective was to assess the efﬁcacy of this regimen ac-
cording to event-free survival (EFS) at 1 year after allo-SCT in patients with
B-NHL. EFS was deﬁned as the time from day of transplant to death from any
cause, disease progression (POD) beyond the preeallo-SCT disease staging,
or the last follow-up. The secondary objectives included safety endpoints of
toxicity, engraftment, acute graft-versus-host disease (aGVHD), chronic
GVHD (cGVHD), TRM, opportunistic infections, and overall survival (OS).
Patient Eligibility
Eligible patients were 18 to 70 years of age who had relapsed or primary
refractory B-NHL and/or who were ineligible for a myeloablative condi-
tioning allo-SCT secondary to either physician choice, advanced age, poor
performance status, end-organ insufﬁciency, signiﬁcant comorbidities, or
recent HDT-ASCT. Patients were also required to have a creatinine clearance
50 cc/min, total bilirubin <2.5 mg/dL in the absence of Gilbert’s syndrome
or congenital hyperbilirubinemia, alanine and aspartate aminotransferases
no more than 3 times upper limit of normal, resting left ventricular ejection
fraction 40%, adjusted diffusion capacity of carbon monoxide 50%, al-
bumin 2.5 mg/dL, and a Karnofsky performance status 70%. Enrollment
required histologic veriﬁcation of CD20þ B-NHL on biopsy within 1 year of
allo-SCT. There was no limit to number of prior lines of therapy.
Key exclusion criteria included active, uncontrolled infection; seropos-
itivity for HIV, hepatitis B core antibody, or hepatitis C; and prior allo-SCT.
Patients with aggressive histology B-NHL by World Health Organization
criteria were required to demonstrate chemosensitivity, either complete or
partial remission, to salvage therapy as determined by International Work-
ing Group Criteria [24] before allo-SCT. They had to be ineligible to proceed
to HDT-ASCT because of either disease involving bone marrow, inability to
successfully harvest 2  106 CD34þ stem cells/kg, or physician decision.
Patients with indolent histology B-NHL, including chronic lymphocytic
leukemia (CLL)/small lymphocytic lymphoma, had to have previously failed
at least 1 line of combination chemotherapy, although chemosensitivity was
not required. Patients with mantle cell lymphoma were eligible in complete
or partial ﬁrst remission if primary histology was either blastoid histology or
p53 expressing on immunohistochemistry.
Chemosensitivity was assessed per standard criteria for B-NHL [24] as
well as additional criteria for CLL/small lymphocytic lymphoma [25] before
allo-SCT. The hematopoietic cell transplantation (HCT) comorbidity index
[26] was retrospectively determined for each patient. Patients required a
fullymatched or single HLA allele disparate related or unrelated donor at 10-
loci (HLA-A, HLA-B, HLA-C, HLA-DRb, or HLA-DQ). The trial is registered on
ClinicalTrials.gov (NCT00425802).
Treatment and Source of Hematopoietic Stem Cells
Rituximab at 375mg/m2was administered day8 or7 before allo-SCT,
given the sensitizing effect of rituximab on B-NHL to cytotoxic chemotherapy
[27,28]. Cyclophosphamide 50 mg/kg was administered for 1 dose on day6
followed by ﬂudarabine 25 mg/m2 administered intravenously daily from
day6 to day2. One dose of TBI at 200 cGywas delivered on day1. Equine
antithymocyte globulin 30 mg/kg was given intravenously daily on day 3
and day 2 to recipients of HLA-matched unrelated or HLA-single-allele
disparate allografts. Posteallo-SCT patients received rituximab 375 mg/m2
weekly for 4 doses beginning day þ21  2 days. The rationale ofadministration and timing of posteallo-SCT rituximab included both B-NHL
progression-free survival beneﬁt in chemotherapy-only programs [29,30]
and the kinetics of cellular effector elements, such as natural killer cells
[31], serving as potential mediators of antibody-dependent cellular cytotox-
icity [32] toward the goal of providing enhanced B-NHL disease control. Pe-
ripheral blood hematopoietic stem cells from healthy donors were collected
using granulocyte colony-stimulating factor 10 mg/kg daily for at least 5 days
with a targeted CD34þ cell dose of 5  106/kg of recipient body weight.
GVHD Prophylaxis and Supportive Care
GVHD prophylaxis initially consisted of cyclosporine A and mycophe-
nolate mofetil as previously described [33]. GVHD prophylaxis was changed
to tacrolimus, sirolimus, and mini-methotrexate at 5 mg/m2 for 3 doses (tac/
siro/mmtx) [34] after 2 of the ﬁrst 8 patients on protocol experienced severe
grades III to IV aGVHD. Patients were managed clinically according to Me-
morial Sloan-Kettering Cancer Center standard guidelines, including anti-
microbial prophylaxis. Monitoring of cytomegalovirus (CMV) reactivation in
peripheral blood initially by CMV pp65 antigenemia assay, and later by CMV
PCR assay (beginning in November 2011), was performed regularly through
day þ100 when either the patient or donor was CMV seropositive. Pre-
emptive therapy was instituted in patients with documented CMV viremia
per institutional standard.
Assessment of Efﬁcacy
To assess efﬁcacy as measured by OS and EFS, disease restaging per
previously aforementioned methods was performed per protocol at
day þ100 and at 6 months, 12 months, 18 months, 24 months, and yearly
thereafter. Cause of death was attributed to B-NHL in cases of POD after allo-
SCT [35].
Assessment of Safety
Adverse events attributable to the preparative regimen and allo-SCT
such as graft failure/engraftment, GVHD, and opportunistic infections
were monitored prospectively. Nonhematologic toxicity within the ﬁrst
30 days was graded according to common terminology criteria for adverse
events v4.0 [36]. Delayed-onset neutropenia after rituximab therapy was
retrospectively collected and analyzed. Neutrophil engraftment was deﬁned
as an absolute neutrophil count >500/mL on 3 consecutive measurements.
Platelet recoverywas deﬁned as 3 consecutivemeasurements of>20,000/mL
unsupported by transfusion.
Donor/host chimerism was routinely performed at 1, 3, and 6 months
from bone marrow and peripheral blood cell subsets for the ﬁrst year after
transplantation using short-tandem repeat ampliﬁed by PCR using the
Promega GenePrint Fluorescent STR Systems (Madison,WI) Gamma STR and
CTTv kits. The PCR products are separated by capillary gel electrophoresis on
an ABI 3730 DNA Analyzer (Life Technologies, USA). The electropherograms
of the current sample are compared to baseline host and donor specimens.
Mixed chimerismwas deﬁned as <90% donor in bone marrow or peripheral
blood. aGVHD was graded based on International Bone Marrow Transplant
Registry criteria [37], wherein grade A ¼ I, B ¼ II, C ¼ III, and D ¼ IV in this
article henceforth. cGVHDwas based on National Institutes of Health criteria
[38]. TRM was deﬁned all cases of death without POD. Attribution to TRM
was assessed by previously published criteria [35]. Total parenteral nutrition
and patient-controlled analgesia were used as surrogates to estimate
mucositis severity.
Statistical Analysis
This study was designed as 2 single-arm phase II trials to explore the
efﬁcacy of the drug regimen and allo-SCT for patients receiving related or
unrelated grafts. Both were designed to differentiate between an unprom-
ising 1-year EFS of 50%, based on historic control subjects, and a promising
EFS of 72%. With a type I error of 10% and a power of 89%, the target accrual
was 30 patients in each cohort for a total sample size of 60. If at least 19 of 30
patients remained alive and event-free at 1 year, the treatment regimen
would be considered promising for further investigation. This article pre-
sents the results as of February 2013. EFS and OS at 1 year and 2 years were
estimated using the Kaplan-Meier method. The log-rank test was used to
compare EFS or OS between different groups. Other efﬁcacy and safety
endpoints were evaluated using competing risk analysis. Death was a
competing risk for POD, death due to nonetransplant-related causes was a
competing risk for TRM, and death or progression was a competing risk for
aGVHD and cGVHD. Gray’s test was used to compare the outcome with
competing risks between different groups [39].
RESULTS
Fifty-one consecutive patients transplanted on this clin-
ical trial fromMarch 2007 to September 2012 were included
Table 1
Patient Characteristics (N ¼ 51)
Characteristic Value
Median age, y 54 (range, 33-67)
Median time from diagnosis to allo-SCT, mo 55 (range, 4-234)
Histology, no. of patients
NHL 30 (59%)
DLBCL 10
FL 14
MCL 4
Other 2
CLL/SLL 21 (41%)
WHO histologic subtypes, no. of patients
Indolent 41 (80%)
Aggressive 10 (20%)
Median HCT-CI 1 (range, 0-5)
Prior therapies 2 (range, 1-5)
Prior ASCT, no. of patients 9 (18%)
Disease status at BMT, no. of patients
CR 22 (43%)
PR 17 (33%)
SD 11 (22%)
PD 1 (2%)
Graft, no. of patients
Related 18 (35%)
Unrelated 33 (65%)
MUD 28
MMUD 5
GVHD prophylaxis
CSA/MMF 8
Tacro/siro/MTX 43
CR indicates complete remission; CSA, cyclosporine A; DLBCL, diffuse large B
cell lymphoma; HCT-CI, hematopoietic cell transplantation comorbidity
index; BMT, bone marrow transplantation; MCL, mantle cell lymphoma;
MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MTX,
methotrexate; MUD, matched unrelated donor; PD, progression of disease;
PR, partial remission; SD, stable disease; SLL, small lymphocytic lymphoma;
siro, sirolimus, WHO, world health organization.
Figure 1. Kaplan-Meier estimate of OS and EFS (N ¼ 51) patients.
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rituximab. The median time from diagnosis to allo-SCT was
55 months (range, 4 to 234 months). Of the 10 patients with
diffuse large B cell lymphoma, 5 were transformed from
previous indolent B-NHL (1 CLL, 2 FL, 1 Waldenström
macroglobulinemia, and 1 marginal zone lymphoma).
Notably, the median HCT comorbidity index was 1. Full pa-
tient demographics are detailed in Table 1.
Forty-ﬁve of 51 patients completed all 4 posteallo-SCT
doses of rituximab. The treating physicians’ rationale for not
completing 4 doses in the 6 patients included cytopenias in
2, early severe GVHD in 1, early death in 1, poor performance
status in 1, and a suspicious brain lesion in 1.Figure 2. Kaplan-Meier estimate of EFS according to chemosensitivity.Efﬁcacy
EFS and OS
With a median follow-up of 38 months (range, 4 to
69 months), the overall 1-year EFS was 82% (95% conﬁdence
interval [CI], 71% to 93%). In the unrelated arm, the primary
endpoint was successfully met with a 77% EFS at 1 year (95%
CI, 64% to 94%). For 18 patients in the related arm, the cur-
rent EFS was 89% (95% CI, 76% to 100%). The 1-year OS of the
entire group was 90% (95% CI, 81% to 98%). The 2-year OS
and EFS were 78% (95% CI, 66% to 90%) and 72% (95% CI, 59%
to 85%), respectively (Figure 1). Of the preeallo-SCT factors
analyzed (ie, B-NHL histology, donor source, number of
prior therapies, previous ASCT, and HCT comorbidity index),
only chemosensitivity demonstrated signiﬁcant prognostic
impact. The EFS of chemosensitive patients was 84% (95% CI,
72% to 96%) at 2 years compared with 30% (95% CI, 2% to58%) in chemorefractory patients (P < .001) (Figure 2),
which translated into an OS beneﬁt in chemosensitive pa-
tients of 86% (95% CI, 74% to 97%) at 2 years compared with
chemorefractory patients of 50% (95% CI, 19% to 81%)
(P ¼ .009).
POD, TRM, and donor lymphocyte infusions
Of the 13 events, 7 were POD and 6 were TRM. Three
patients remained alive after POD. The cumulative incidence
of TRM at 1 year was 8% (95% CI, 0% to 16%) and at 2 years was
13% (95% CI, 3% to 23%). The cumulative incidence of POD at
1 year was 8% (95% CI, 0% to 16%) and at 2 years was 13% (95%
CI, 3% to 23%) (Figure 3). Five of 6 transplant-related deaths
were attributable to GVHD. Two of the ﬁrst 8 patients expired
secondary to grades III and IV aGVHD while on cyclosporine
A/mycophenolate mofetil GVHD prophylaxis, at which time
prophylaxis was changed to tac/siro/mmtx. Two patients
received donor lymphocyte infusions within 2 years post-
transplant. One patient received a donor lymphocyte infu-
sion for treatment of CMV viremia and subsequently died of
complications of GVHD on day þ424. Another patient
received a donor lymphocyte infusion for POD and subse-
quently died of B-NHL on day þ254.
Figure 3. Cumulative incidence of (A) TRM and (B) POD.
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Engraftment and chimerism
The median total nucleated cell dose and CD34þ cell dose
were 13.2108/kg (range,1.9 to 35.0) and 9.9 106/kg (range,
1.1 to 31.7), respectively. All patients engrafted neutrophils at
a median time of 15 days (range, 10 to 25) posteallo-SCT.
Median time to platelet engraftment was 12 days (range, 6 to
40). Full donor chimerism (deﬁned as 90% donor) was
achieved in 80% and 92% of assessable patients at 1month and
3 months posteallo-SCT, respectively. Three patients had a
mixed marrow chimerism of 75% (CLL, eventual TRM sec-
ondary to GVHD at day þ382), 65% (transformed Walden-
strom macroglobulinemia/diffuse large B cell lymphoma POD
with Waldenström macroglobulinemia in bone marrow
day þ98), and 60% (CLL POD in bone marrow at day þ99) at
3 months posteallo-SCT. T cell chimerism in peripheral blood
was 89%, 91%, and 95% at 3, 6, and 12 months, respectively.
Graft-versus-host disease
The cumulative incidence of moderate to severe grades II
to IV aGVHD at 3 and 6 months after allo-SCT was 18% (95%
CI, 7% to 29%) and 25% (95% CI, 13% to 38%), respectively,
whereas the cumulative incidence of severe grades III to IV
aGVHD at 3 and 6 months after allo-SCT was 8% (95% CI, 0 to
16%) and 11% (95% CI, 2% to 20%), respectively (Figure 4A).
There was no difference in incidence or severity of aGVHD
between related and unrelated donors. The cumulative
incidence of cGVHD at 1 year and 2 years posteallo-SCT was
14% (95% CI, 3% to 24%) and 29% (95% CI, 15% to 44%),
respectively, whereas the cumulative incidence of moderate
to severe cGVHDwas 7% (95% CI, 0 to 15%) and 10% (95% CI,1%
to 20%) at 1 and 2 years, respectively, after allo-SCT
(Figure 4B).Toxicity
One patient died secondary to Stevens-Johnson syn-
drome, representing the only grade V nonhematologic
toxicity within 30 days of allo-SCT on study. Four cases of
hyperglycemia (grade III) and 2 cases of alanine amino-
transferase elevation (grade III) were the other grades III to IV
nonhematologic toxicities in the ﬁrst 30 days after allo-SCT.None of the patients required narcotic infusions for muco-
sitis during their nadir. Twenty percent of patients required
total parenteral nutrition for poor caloric intake.
Of the 49 assessable patients that received at least 1 dose
of posteallo-SCT rituximab, 30 patients (61%) experienced
72 episodes of grade III or IV neutropenia at a median of
10 weeks after the ﬁrst dose of rituximab (range, 1 day to
27 weeks). For these 72 episodes, 92 doses of ﬁlgrastim and
22 doses of pegylated ﬁlgrastim were administered at the
treating physicians’ discretion. Of the 72 neutropenic epi-
sodes, 5 (7%) were associated with fever (Table 2). Of the
remaining noncomplicated neutropenic episodes, all recov-
ered to no more than grade II after a median of 1 dose of
growth factor (range, 1 to 8). Two cases of new grade III
thrombocytopenia occurred at 7 and 26 weeks, respectively,
after initiation of rituximab posteallo-SCT without other
explanation. Nine other cases of new grades III to IV throm-
bocytopenia occurred (from 1 to 35 weeks after rituximab)
likely contributed by thrombocytopenic thrombotic purpura
(n ¼ 2), active bloodstream infection (n ¼ 1), CMV infection
treated with ganciclovir or valganciclovir (n ¼ 4), severe
(grades III to IV) aGVHD requiring hospitalization, or mod-
erate to severe cGVHD (n ¼ 7).
Immune Reconstitution and Viral Opportunistic
Infections
The median CD4þ count increased incrementally from
253/mL (interquartile range, 160 to 343/mL) at 3 months, to
312/mL at 6months (interquartile range,174 to 457/mL), and to
333/mL at 1 year (interquartile range, 18 to 1317/mL). Twenty-
ﬁve percent of patients at risk for CMV infection reactivated
and were treated pre-emptively. Four of the 6 patients who
required treatment had been transplanted from unrelated
donors. None of the patients developed CMV end-organ
disease. There was no Epstein-Barr viral reactivation.
DISCUSSION
Herein we report results of a phase II study using NMA
conditioning of cyclophosphamide, ﬂudarabine, and low-
dose TBI incorporating perieallo-SCT rituximab in patients
with B-NHL with a durable, 2-year EFS of 72% and OS of 78%.
Figure 4. Cumulative incidence of (A) aGVHD and (B) cGVHD.
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of multiple B-NHL histologies conditioned with TBI con-
taining NMA regimen receiving allografts from predomi-
nately unrelated donors. Although the early experience with
myeloablative allo-SCT generally yielded poor results sec-
ondary to prohibitively high TRM [11,12], the widespread
implementation of RIC has abrogated the risk of TRM often to
<25% [13-21], translating into improved outcomes of pa-
tients with lymphoma [40]. In the setting of RIC, disease
control has largely been attributed to allogeneic graft-
versus-lymphoma effects [13,14]. These results of our pro-
spective study compare favorably with other reported RIC
allo-SCT studies for B-NHL with <10% TRM and POD both at
1 year posteallo-SCT. Reasons for these encouraging results
are likely multifactorial, including incorporation of mono-
clonal antibody therapy with rituximab, B-NHL disease
control with TBI, and potentially B-NHL active and effective
GVHD prophylaxis with the addition of sirolimus.
Our data corroborate other studies [17,20,21,41-43] in
deﬁning chemosensitivity as a signiﬁcant prognostic factor.
We observed a signiﬁcantly higher 2-year EFS of 84% in
chemosensitive patients compared with 30% with stable
disease before allo-SCT. Although most events in our che-
morefractory patients were due to POD, other groups have
reported an independent impact of chemosensitivity on TRMTable 2
Characteristics of 5 Cases of Febrile Neutropenia Episodes After 1 Dose
Post-Allo-SCT Rituximab
Day
PosteAllo-SCT
Clinical Setting Result
45 Active CMV viremia and acute
grade III gastrointestinal GVHD
Recovered
68 Active acute grade IV
gastrointestinal GVHD
Died of GVHD
while neutropenic
139 Acute cholecystitis Recovered
141 Febrile neutropenia without
source
Recovered
171 Iatrogenic MSSA abscess and
bacteremia after a procedure
Recovered
MSSA indicates methicillin-sensitive Staphylococcus aureus.[16,41,44]. The relatively low HCT comorbidity index (me-
dian, 1) and the limited number of previous therapies (me-
dian, 2) in our cohort may have contributed to lower TRM.
This observation suggests the potentially cumulative organ
toxicity and immune suppression with increasing lines of
therapy and/or deleterious physiologic effects of active
lymphoma. Given these ﬁndings, the negative prognostic
impact of chemotherapy resistance must prompt careful
consideration about additional chemotherapy regimens
before RIC/NMA allo-SCT, especially considering the bur-
geoning development of highly active, and relatively
nontoxic, targeted pathway inhibitors [45,46].
The incorporation of novel and relatively safe antieB-NHL
activity with rituximab may afford enhanced disease control
before the development of graft-versus-lymphoma effects,
presumed to take months after NMA allo-SCT. This inter-
vention is not without consequence because 61% of patients
experienced grades III to IV neutropenia, mostly delayed-
onset neutropenia, at a median of 10 weeks after initiation
of posteallo-SCT rituximab. Delayed-onset neutropenia was
previously reported in >50% of patients receiving rituximab
after HDT-ASCT [47] and has been described in the non-
transplantation setting [48], also at a median of 10 weeks
after rituximab administration as we report here. In our se-
ries this typically was without consequence, because 7% of
episodes were associated with fever, with identiﬁable and
concurrent infection with CMV, acute cholecystitis and ab-
scess/bacteremia in 3 of 5 cases along with severe aGVHD
complicating 2 of 5 cases.
The strategy of peri-NMA allo-SCT was ﬁrst reported by
the group at M.D. Anderson Cancer Center in chemosensitive
patients with multiply relapsed and refractory FL, wherein
long-term follow-up has demonstrated extremely favorable
and durable progression-free survival in predominately HLA-
matched sibling allo-SCT [19]. These results are similar to our
cohort of chemosensitive patients, uniquely across all histol-
ogies. Outcomes from these studies incorporating peri-NMA
allo-SCT transplant anti-CD20 monoclonal antibodies appear
to compare favorably with those that do not. For example, in a
study with a similar ﬂudarabine and cyclophosphamide
conditioning backbone,>30% of chemosensitive patientswith
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[49]. In our study, the addition of TBI at 200 cGy not only
provides additional immune suppression with very low inci-
dence of mixed chimerism for an NMA regimen but may
actually contribute to a survival beneﬁt, as recently reported
in a large registry study of RIC allo-SCT for NHL after ASCT
failure [50]. Finally, B cell depletion with rituximab may
contribute to reduced TRM and potentially improved survival
by its impact on cGVHD [51,52]. This would need to be vali-
dated in a larger randomized prospective study.
The conditioning regimenwas extremelywell tolerated in
this trial. Despite this, 5 of 6 transplant-related deaths were
attributable to complications of GVHD. This underscores the
importance of preventing GVHD in improving OS post-NMA
allo-SCT.We report a low incidence of grades II to IV (18% and
25%) and III to IV aGVHD (8% and 11%) at 3 and 6 months,
respectively, posteallo-SCT with most patients having
received tac/siro/mmtx GVHD prophylaxis. Our incidence of
aGVHD is similar to the original reports for this GVHD pro-
phylaxis regimen in RIC allo-SCT [34,53]. Although the
addition of sirolimus to calcineurin inhibitors is not without
risk, such as dyslipidemia [54] and thrombotic micro-
angiopathy [55], the low incidence of aGVHD [56], particu-
larly severe aGVHD [57], and cGVHD [56] make it quite
attractive. Moreover, based on the reported contribution of
the mammalian target of rapamycin pathway, which is tar-
geted by sirolimus, to prosurvival signals in several histologic
subsets of NHL [58], this immune suppressive regimen may
provide added protection from progression of lymphoma
[59]. We observed a relatively low incidence of cGVHD of 29%
at 2 years post-SCT, with most being mild (incidence of
moderate to severe cGVHD, 10%). The results or our institu-
tional experience with tac/siro/mmtx in conjunction with
RIC allo-SCT across all hematologic malignancies will be re-
ported in a forthcoming article. The potential contribution of
equine antithymocyte globulin [60-62] and/or rituximab in
the perieallo-SCT period [51,52] to a reduction in cGVHD
would need to be veriﬁed in a prospective randomized trial.
In conclusion, we report favorable EFS in this prospective
phase II study incorporating rituximab and low-dose TBI into
an NMA allo-SCT for B-NHL, especially in chemosensitive
patients. In light of these ﬁndings, early referral for NMA
allo-SCT should be considered in poor-risk B-NHL patients
while chemosensitivity is preserved. The contributions of
rituximab, sirolimus, equine antithymocyte globulin, and
low-dose TBI to the success of this treatment program needs
to be validated in a prospective randomized trial. Potential
shortfalls of this phase II study include relatively non-
comorbid patients (median HCT comorbidity index of 1)
treated at a single tertiary referral center. Finally, given our
success and other centers’ success introducing drugs such as
rituximab and sirolimus into RIC allo-SCT regimens, future
emphasis should be placed on identifying and developing
targeted lymphotoxic pharmaceuticals [63] that may provide
both anti-B-NHL disease activity and effective GVHD pre-
vention that may continue to improve the OS of these
patients.
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